scd – Scalper1

Bluebird Bio Craters After Gene Therapy Disappoints

Biotech Bluebird Bio plunged to a 52-week low Monday after the latest data on its gene therapy for severe anemia failed to live up to the promise of earlier data, leading to several downgrades. On Sunday at the annual American Society of Hematology (ASH) conference, Bluebird (BLUE) detailed its early-stage findings on patients with sickle-cell disease (SCD) and beta-thalassemia, two genetic diseases that cause anemia, who were treated with its

IPO Stock Watch: Global Blood Doubles On First Day

Global Blood Therapeutics (GBT) shrugged off the recent slump in biotech stocks and screamed up 130% as of late afternoon on its first day of trading Wednesday, after pricing its 6-million-share IPO at 20, above the expected range. The initial public offering raised $120 million. Global Blood is developing treatments for blood disorders, particularly sickle-cell disease (SCD), a genetic condition that causes anemia. Its lead candidate entered